中国乙型肝炎综合干预包投资案例:应用模型辅助国家策略规划
该研究建立中国HBV动态模拟模型,从社会视角评估综合预防与治疗干预包的影响、成本和投资回报。
要点
- 综合干预包社会投资回报为每投入1美元回报1.57美元。
核心结论
- 未来数十年HBV相关死亡增加是中国重大公共卫生威胁,需要积极病例发现和获得优化抗病毒治疗来缓解风险。
研究设计与样本
- 开发中国HBV动态模拟模型,从社会视角评估综合预防和治疗干预包的影响、成本和投资回报。
主要发现
- 综合干预包社会投资回报为每投入1美元回报1.57美元。
临床怎么用
- 应用模型支持国家对话和政策规划,推动积极病例发现和优化抗病毒治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In 2016, the first global viral hepatitis elimination targets were endorsed. An estimated one-third of the world's population of individuals with chronic hepatitis B virus (HBV) infection live in China and liver cancer is the sixth leading cause of mortality, but coverage of first-line antiviral treatment was low. In 2015, China was one of the first countries to initiate a consultative process for a renewed approach to viral hepatitis. We present the investment case for the scale-up of a comprehensive package of HBV interventions. METHODS: A dynamic simulation model of HBV was developed and used to simulate the Chinese HBV epidemic. We evaluated the impact, costs, and return on investment of a comprehensive package of prevention and treatment interventions from a societal perspective, incorporating costs of management of end-stage liver disease and lost productivity costs. RESULTS: Despite the successes of historical vaccination scale-up since 1992, there will be a projected 60 million people still living with HBV in 2030 and 10 million HBV-related deaths, including 5.7 million HBV-related cancer deaths between 2015 and 2030. This could be reduced by 2.1 million by highly active case-finding and optimal antiviral treatment regimens. The package of interventions is likely to have a positive return on investment to society of US$1.57 per US dollar invested. CONCLUSIONS: Increases in HBV-related deaths for the next few decades pose a major public health threat in China. Active case-finding and access to optimal antiviral treatment are required to mitigate this risk. This investment case approach provides a real-world example of how applied modeling can support national dialog and inform policy planning.
引用
- Nayagam S, Chan P, Zhao K, et al. Investment Case for a Comprehensive Package of Interventions Against Hepatitis B in China: Applied Modeling to Help National Strategy Planning. Clin Infect Dis. 2021. PMID: 32255486. doi:10.1093/cid/ciaa134
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。